Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 11/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607248 | 0.93 | LCK (0.48) | LCKEGFRALKMKNK2IGF1R | |
| SCHEMBL18607249 | 0.88 | LCK (0.48) | LCKEGFRALKIGF1RKCNH2 | |
| SCHEMBL18607107 | 0.88 | LCK (0.43) | LCKEGFRALKMKNK2IGF1R | |
| SCHEMBL18607247 | 0.88 | LCK (0.47) | LCKEGFRALK | |
| SCHEMBL18606983 | 0.87 | LCK (0.51) | LCKEGFRMKNK2IGF1RKCNH2 | |
| SCHEMBL18607246 | 0.87 | LCK (0.47) | LCKEGFRALKMKNK2IGF1R | |
| SCHEMBL18607339 | 0.86 | EGFR (0.56) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL18606892 | 0.84 | LCK (0.51) | LCKEGFRIGF1RKCNH2CCNT1 | |
| SCHEMBL18606898 | 0.83 | LCK (0.45) | LCKEGFRALKMKNK2 | |
| SCHEMBL18606904 | 0.83 | LCK (0.45) | LCKEGFRALKMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | LCK 157/4885EGFR 2/4885ALK 5/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | LCK 126/4885EGFR 2/4885ALK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.